Article

Dr. Phillips named physician-in-charge of urologic oncology at Beth Israel

New York?John L. Phillips, MD, is the new physician-in-charge of urologic oncology at Beth Israel Medical Center, New York.

Related Videos
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, answers a question during a Zoom video interview
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
1 expert in this video
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
1 expert in this video
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
1 expert in this video
Adoption of New Treatment Modalities to Treat BPH
1 expert is featured in this series.
Safety data on Black patients from ARANOTE
2 experts are featured in this series.
Current Unmet Needs in ccRCC Diagnosis
2 experts are featured in this series.
Decision-Making in Small Renal Masses
Related Content
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
May 28th 2025

Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy

Hannah Clarke
These data are intended to support a new drug application to the FDA in the second half of 2025.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
May 27th 2025

Combination therapy linked to longer OS vs ADT in veterans with mHSPC

Hannah Clarke
However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Expert discusses the promise of emerging MISTs for BPH
May 23rd 2025

Expert discusses the promise of emerging MISTs for BPH

James C. Ulchaker, MD Hannah Clarke
James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.
Man talking with doctor | Image Credit: © Pcess609 - stock.adobe.com
May 22nd 2025

Case study: 69-year-old Black man with mHSPC

Urology Times staff
"When we select abiraterone for our patients with mHSPC, there's a choice between generic and branded options," says Paul C. Dato MD.
© 2025 MJH Life Sciences

All rights reserved.